Variable | Aspergillus positive (n = 8) | Aspergillus negative (n = 96) | P value |
---|---|---|---|
Demographics | |||
 Age, mean (SD), years | 73 (13) | 53 (15) | < 0.001 |
 Male sex, no. (%) | 8 (100) | 54 (56.3) | 0.02 |
Underlying disease, no. (%) | |||
 Any | 7 (87.5) | 36 (37.5) | 0.008 |
 Hypertension | 7 (87.5) | 31 (32.3) | 0.003 |
 Diabetes mellitus | 2 (25) | 11 (11.5) | 0.262 |
 Heart disease | 1 (12.5) | 6 (6.3) | 0.439 |
 COPD | 2 (25) | 2 (2.1) | 0.029 |
 Cancer | 0 (0) | 1 (1.0) | 1 |
 Immunodeficiency | 0 (0) | 0 (0) | – |
 Chronic kidney disease | 2 (25) | 0 (0) | 0.005 |
 Pregnancy | 0 (0) | 3 (3.1) | 1 |
Smoking in the past 1Â year, no. (%) | 2 (25) | 6 (6.3) | 0.115 |
Severe/critical type, no. (%) | 8 (100) | 70 (72.9) | 0.196 |
Complications, no. (%) | |||
 ARDS | 4 (50) | 38 (39.6) | 0.712 |
 Shock | 0 (0) | 0 (0) | – |
 Liver damage | 1 (12.5) | 7 (7.3) | 0.485 |
 Acute kidney injury | 1 (12.5) | 0 (0) | 0.077 |
Treatment, no. (%) | |||
 Mechanical ventilation | 4 (50) | 11 (11.5) | 0.014 |
 ECMO | 1 (12.5) | 3 (3.1) | 0.278 |
 CRRT | 1 (12.5) | 1 (1.0) | 0.149 |
Corticosteroid treatment, no. (%) | 6 (75) | 57 (59.4) | 0.475 |
 Maximum methylprednisolone equivalent dosage, median (IQR), mg/day | 70 (5–80) | 40 (0–60) | 0.191 |
Administration of antiviral treatment | 8 (100) | 89 (92.7) | 1 |
Initial antibiotic treatment, no./total (%) | 6 (75) | 46 (47.9) | 0.269 |
 3rd-generation cephalosporin | 0 (0) | 7 (7.3) | 1 |
 Fluoroquinolone | 3 (37.5) | 26 (27.1) | 0.683 |
 β-Lactamase inhibitors | 6 (75) | 17 (17.7) | 0.001 |
ICU admission, no./total (%) | 8 (100) | 18 (18.8) | 0 |